United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. phytonadione injectable emulsion, usp is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates.

United States - English - NLM (National Library of Medicine)

henry schein, inc. - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - 1.1 treatment of hypoprothrombinemia due to vitamin k deficiency or interference phytonadione injectable emulsion, usp is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity; - anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. 1.2 prophylaxis and treatment of vitamin k-deficiency bleeding in neonates phytonadione injectable emulsion, usp is indicated for prophylaxi

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione 10 mg in 1 ml - vitamin k1 injection (phytonadione injectable emulsion, usp) is indicated in the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. vitamin k1 injection is indicated in: • anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; • prophylaxis and therapy of hemorrhagic disease of the newborn; • hypoprothrombinemia due to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; • other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. hypersensitivity to any component of this medication.

United States - English - NLM (National Library of Medicine)

hospira, inc. - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione 2 mg in 1 ml - vitamin k1 injection (phytonadione injectable emulsion, usp) is indicated in the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. vitamin k1 injection is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; hypoprothrombinemia secondary to factors limiting

United States - English - NLM (National Library of Medicine)

a-s medication solutions - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - mephyton is indicated in the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. mephyton tablets are indicated in: hypersensitivity to any component of this medication.

Canada - English - Health Canada

boiron laboratoires - phytolacca decandra - drops - 2ch - phytolacca decandra 2ch - homeopathic products

Canada - English - Health Canada

boiron laboratoires - phytolacca decandra - tablet - 2ch - phytolacca decandra 2ch - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - phytolacca decandra - tablet - 1dh - phytolacca decandra 1dh - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - phytolacca decandra - drops - 1ch - phytolacca decandra 1ch - homeopathic products

Canada - English - Health Canada

koegler laboratories inc. - phytolacca decandra - powder - 4x - phytolacca decandra 4x - homeopathic products